After a dosing arm of a trial - normally a pharma doesn't need to go running to the FDA to move into the selected dose (even the trial protocol says that) - unless the FDA may have a problem with what you want to do.
Just saying.
Learn FDA protocol. And stop saying the drug impacts DNA because some non-medico private citizen of Otago, New Zealand said it in a discussion paper.
My conclusions are founded in a more robust inquiry.
Where we at?, page-691
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $101.4M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.5¢ | 28.5¢ | $79.93K | 274.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12951 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 23984 | 3 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |